Pathophysiological basis of migraine prophylaxis

Progress in Neurobiology

Volumn 89, Issue 2, 2009, Pages 176-192

  Galletti, Francesca ^a,b   Cupini, Letizia Maria ^c   Corbelli, Ilenia ^a,b   Calabresi, Paolo ^a,b   Sarchielli, Paola ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

Adrenergic blockers; Antidepressants; Antiepileptic drugs; Calcium channel blockers; Spreading depression

Indexed keywords

AMITRIPTYLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUNARIZINE; LAMOTRIGINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LISINOPRIL; MAGNESIUM; MELATONIN; OLANZAPINE; PETASITES HYBRIDUS EXTRACT; PIZOTIFEN; PLACEBO; POLYUNSATURATED FATTY ACID; PROPRANOLOL; RIBOFLAVIN; SEROTONIN ANTAGONIST; TANACETUM PARTHENIUM EXTRACT; TIMOLOL; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANGINA PECTORIS; ASTHENIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CONSTIPATION; DEMENTIA; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIET SUPPLEMENTATION; DIZZINESS; DOPAMINERGIC SYSTEM; DROWSINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; DYSTONIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INCREASED APPETITE; INSOMNIA; LANGUAGE DISABILITY; LETHARGY; LIP DISEASE; MANIA; MEMORY DISORDER; MENSTRUAL MIGRAINE; MIGRAINE; MIGRAINE WITH AURA; MOUTH PAIN; NAUSEA; NERVE CELL EXCITABILITY; NEUROGENIC INFLAMMATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; PARESTHESIA; PARKINSONISM; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SENSITIZATION; SIDE EFFECT; SLEEP DISORDER; SPREADING CORTICAL DEPRESSION; TARDIVE DYSKINESIA; TASTE DISORDER; TONGUE ULCER; TRANSFORMED MIGRAINE; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CORTICAL SPREADING DEPRESSION; HUMANS; INFLAMMATION; MIGRAINE DISORDERS; NEUROTRANSMITTER AGENTS;

EID: 70249139793     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.07.005     Document Type: Review

References (342)

1. Ablad B., and Dahlöf C. Migraine and beta-blockade: modulation of sympathetic neurotransmission. Cephalalgia 6 (1986) 7-13
2. Afridi S.K., Giffin N.J., Kaube H., Friston K.J., Ward N.S., Frackowiak R.S., and Goadsby P.J. A positron emission tomographic study in spontaneous migraine. Arch. Neurol. 62 (2005) 1270-1275
3. Afridi S.K., Matharu M.S., Lee L., Kaube H., Friston K.J., Frackowiak R.S., and Goadsby P.J. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128 (2005) 932-939
4. Agosti R., Duke R.K., Chrubasik J.E., and Chrubasik S. Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: a systematic review. Phytomedicine 13 (2006) 743-746
5. Akerman S., and Goadsby P.J. Dopamine and migraine: biology and clinical implications. Cephalalgia 27 (2007) 1308-1314
6. Akerman S., Williamson D.J., and Goadsby P.J. Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism. Br. J. Pharmacol. 140 (2003) 558-566
7. + ion channel blockade. Brain Res. 1229 (2008) 27-36
8. Akkermann J.W.M., and Van den Hoven W.E. The influence of cyclandelate on Ca++-translocation in human platelets. Drugs 33 (1987) 53-59
9. Alemdar M., Akman O., Selekler H.M., Komsuoǧlu S.S., and Ateş N. Does metoprolol inhibit the cortical spreading depression? Acute effects of systematic metoprolol on CSD in rats. Cephalalgia 27 (2007) 1010-1013
10. Andersson K.E., and Vinge E. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 39 (1990) 355-373
11. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26 (2005) 785-793
12. Arulmozhi D.K., Veeranjaneyulu A., and Bodhankar S.L. Migraine: current concepts and emerging therapies. Vascul. Pharmacol. 43 (2005) 176-187
13. Aruoma O.I., Smith C., Cecchini R., Evans P.J., and Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by beta-blockers and by agents that interfere with calcium metabolism. A physiologically-significant process?. Biochem. Pharmacol. 42 (1991) 735-743
14. Aston-Jones G., Chen S., Zhu Y., and Oshinsky M.L. A neural circuit for circadian regulation of arousal. Nat. Neurosci. 4 (2001) 732-738
15. Aurora S. Botulinum toxin type A for the treatment of migraine. Expert. Opin. Pharmacother. 7 (2006) 1085-1095
16. Avanzini G., and Franceschetti S. Cellular biology of epileptogenesis. Lancet Neurol. 2 (2003) 33-42
17. Ayajiki K., Okamura T., and Toda N. Flunarizine, an anti-migraine agent, impairs nitroxidergic nerve function in cerebral arteries. Eur. J. Pharmacol. 329 (1997) 49-53
18. Ayata C., Jin H., Kudo C., Dalkara T., and Moskowitz M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59 (2006) 652-661
19. Bach F.W. Beta-endorphin in migraine. Cephalalgia 12 (1992) 390-391
20. Bangalore S., Messerli F.H., Kostis J.B., and Pepine C.J. Cardiovascular protection using beta-blockers: a critical review of the evidence. J. Am. Coll. Cardiol. 50 (2007) 563-572
21. Bánk J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 34 (1994) 476-478
22. Battistella P.A., Ruffilli R., Cernetti R., Pettenazzo A., Baldin L., Bertoli S., and Zacchello F. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache 33 (1993) 36-39
23. 2+ channels. Neuropharmacology 46 (2004) 743-749
24. Bender W.I. ACE inhibitors for prophylaxis of migraine headaches. Headache 135 (1995) 470-471
25. Bendtsen L., and Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type. Neurology 62 (2004) 1706-1711
26. Bergerot A., Storer R.J., and Goadsby P.J. Dopamine inhibits trigeminovascular transmission in the rat. Ann. Neurol. 61 (2007) 251-262
27. Berridge C.W., and Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Rev. 42 (2003) 33-84
28. Berrino L., Oliva P., Rossi F., Palazzo E., Nobili B., and Maione S. Interaction between metabotropic and NMDA glutamate receptors in the periaqueductal grey pain modulatory system. Naunyn Schmiedebergs Arch. Pharmacol. 364 (2001) 437-443
29. Bigal M.E., and Lipton R.B. Modifiable risk factors for migraine progression. Headache 46 (2006) 1334-1343
30. Bigal M.E., Lipton R.B., and Stewart W.F. The epidemiology and impact of migraine. Curr. Neurol. Neurosci. Rep. 4 (2004) 98-104
31. Binder W.J., Brin M.F., Blitzer A., Schoenrock L.D., and Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123 (2000) 669-676
32. Black J.D., and Dolly J.O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell. Biol. 103 (1986) 535-544
33. Boehnke C., Reuter U., Flach U., Schuh-Hofer S., Einhäupl K.M., and Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur. J. Neurol. 11 (2004) 475-477
34. Boska M.D., Welch K.M., Barker P.B., Nelson J.A., and Schultz L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 58 (2002) 1227-1233
35. Bourre J.M. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J. Nutr. Health Aging 8 (2004) 163-174
36. Brandes J.L., Saper J.R., Diamond M., Couch J.R., Lewis D.W., Schmitt J., Neto W., Schwabe S., Jacobs D., and MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291 (2004) 965-973
37. Brandes J.L., Visser W.H., Farmer M.V., Schuhl A.L., Malbecq W., Vrijens F., Lines C.R., Reines S.A., and Protocol 125 study group. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. Headache 44 (2004) 581-586
38. Brune K., Bickel D., and Peskar B.A. Gastro protective effects by extracts of Petasites hybridus: the role of inhibition of peptido-leukotriene synthesis. Planta Med. 59 (1993) 494-496
39. Buchanan T.M., and Ramadan N.M. Prophylactic pharmacotherapy for migraine headaches. Semin. Neurol. 26 (2006) 188-198
40. Burstein R., Yarnitsky D., Goor-Aryeh I., Ransil B.J., and Bajwa Z.H. An association between migraine and cutaneous allodynia. Ann. Neurol. 47 (2000) 614-624
41. Burstein R., Levy D., and Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev. Neurol. 161 (2005) 658-660
42. Buzzi M.G., and Moskowitz M.A. The pathophysiology of migraine: year 2005. J. Headache Pain 6 (2005) 105-111
43. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., Hemrick-Luecke S.K., and Wong D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25 (2001) 871-880
44. Cady R., and Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48 (2008) 900-913
45. Calabresi P., and Cupini L.M. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol. Sci. 26 (2005) 62-68
46. Calabresi P., Centonze D., and Bernardi G. Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology 55 (2000) 1249-1255
47. Calabresi P., Centonze D., Pisani A., Cupini L., and Bernardi G. Synaptic plasticity in the ischaemic brain. Lancet Neurol. 2 (2003) 622-629
48. Calabresi P., Cupini L.M., Centonze D., Pisani F., and Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann. Neurol. 53 (2003) 693-702
49. Calabresi P., Galletti F., Rossi C., Sarchielli P., and Cupini L.M. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol. Sci. 28 (2007) 188-195
50. Campo-Arias A. Antidepressants in migraine prophylaxis: an approximation. Rev. Neurol. 38 (2004) 864-868
51. Capobianco D.J., and Dodick D.W. Diagnosis and treatment of cluster headache. Semin. Neurol. 26 (2006) 242-259
52. Castillo J., Muñoz P., Guitera V., and Pascual J. Epidemiology of chronic daily headache in the general population. Headache 39 (1999) 190-196
53. Cerbo R., Casacchia M., Formisano R., Feliciani M., Cusimano G., Buzzi M.G., and Agnoli A. Flunarizine-pizotifen single dose double-blind cross-over trial in migraine prophylaxis. Cephalalgia 6 (1986) 15-18
54. Cerbo R., Barbanti P., Buzzi M.G., Fabbrini G., Brusa L., Roberti C., Zanette E., and Lenzi G.L. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin. Neuropharmacol. 20 (1997) 36-41
55. Chalon S., Vancassel S., Zimmer L., Guilloteau D., and Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 36 (2001) 937-944
56. Chapman A., Keane P.E., Meldrum B.S., Simiand J., and Vernieres J.C. Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 19 (1982) 315-359
57. Choudhuri R., Cui L., Yong C., Bowyer S., Klein R.M., Welch K.M., and Berman N.E. Cortical spreading depression and gene regulation: relevance to migraine. Ann. Neurol. 51 (2002) 499-506
58. Chugani D.C., Niimura K., Chaturvedi S., Muzik O., Fakhouri M., Lee M.L., and Chugani H.T. Increased brain serotonin synthesis in migraine. Neurology 53 (1999) 1473-1479
59. Ciancarelli I., Tozzi-Ciancarelli M.G., Di Massimo C., Marini C., and Carolei A. Urinary nitric oxide metabolites and lipid peroxidation by products in migraine. Cephalalgia 23 (2003) 39-42
60. Ciancarelli I., Tozzi-Ciancarelli M.G., Di Massimo C., Marini C., and Carolei A. Flunarizine effects on oxidative stress in migraine patients. Cephalalgia 24 (2004) 528-532
61. Claustrat B., Loisy C., Brun J., Beorchia S., Arnaud J.L., and Chazot G. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache 29 (1989) 242-245
62. Colombo B., Annovazzi P.O., and Comi G. Therapy of primary headaches: the role of antidepressants. Neurol. Sci. 25 (2004) S171-S175
63. Coppola F., Rossi C., Mancini M.L., Corbelli I., Nardi K., Sarchielli P., and Calabresi P. Language disturbances as a side effect of prophylactic treatment of migraine. Headache 48 (2008) 86-94
64. Coppola G., Pierelli F., and Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine?. Cephalalgia 27 (2007) 1427-1439
65. Costa C., Leone G., Saulle E., Pisani F., Bernardi G., and Calabresi P. Coactivation of GABA(A) and GABA(B) receptor results in neuroprotection during in vitro ischemia. Stroke 35 (2004) 596-600
66. Costa C., Martella G., Picconi B., Prosperetti C., Pisani A., Di Filippo M., Pisani F., Bernardi G., and Calabresi P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 37 (2006) 1319-1326
67. Couch J.R., Ziegler D.K., and Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. Neurology 26 (1976) 121-127
68. Crowder D., and Maclay W.P. Pizotifen once daily in the prophylaxis of migraine: results of a multi-centre general practice study. Curr. Med. Res. Opin. 9 (1984) 280-285
69. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004) 125-133
70. Cupini L.M., Calabresi P., Silvestrini M., Troisi E., Matteis M., Argiró G., and Bernardi G. Prolactin response to bromocriptine in flunarizine-treated migrainous women. Clin. Neuropharmacol. 20 (1997) 234-238
71. Cupini L.M., Massa R., Floris R., Manenti G., Martini B., Tessa A., Nappi G., Bernardi G., and Santorelli F.M. Migraine-like disorder segregating with mtDNA 14484 Leber hereditary optic neuropathy mutation. Neurology 60 (2003) 717-719
72. Cupini L.M., Bari M., Battista N., Argirò G., Finazzi-Agrò A., Calabresi P., and Maccarrone M. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 26 (2006) 277-281
73. Cutrer F.M. Antiepileptic drugs: how they work in headache. Headache 41 (2001) S3-S10
74. Cutrer F.M., Limmroth V., and Moskovitz M.A. Possibile mechanisms of valproate in migraine prophylaxis. Cephalagia 17 (1997) 93-100
75. Dalkara T., Zervas N.T., and Moskowitz M.A. From spreading depression to the trigeminovascular system. Neurol. Sci. 27 (2006) S86-S90
76. D'Amato C.C., Pizza V., Marmolo T., Giordano E., Alfano V., and Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 39 (1999) 716-719
77. D'Andrea G., Granella F., Cadaldini M., and Manzoni G.C. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 19 (1999) 64-66
78. de Souza Carvalho D., Fragoso Y.D., Coelho F.M., and Pereira M.M. Asthma plus migraine in childhood and adolescence: prophylactic benefits with leukotriene receptor antagonist. Headache 42 (2002) 1044-1047
79. de Vries B., Frants R.R., Ferrari M.D., and van den Maagdenberg A.M. Molecular genetics of migraine. Hum. Genet. 20 (2009) Epub ahead of print
80. De Weerdt C.J., Bootsma H.P.R., and Hendricks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of feverfew preparation. Phytomedicine 3 (1996) 225-230
81. Denuelle M., Fabre N., Payoux P., Chollet F., and Geraud G. Hypothalamic activation in spontaneous migraine attacks. Headache 47 (2007) 1418-1426
82. Di Trapani G., Mei D., Marra C., Mazza S., and Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin. Ter. 151 (2000) 145-148
83. Diener H.C. Pharmacological approaches to migraine. J. Neural. Transm. Suppl. 64 (2003) 35-63
84. Diener H.C., Scholz E., Dichgans J., Gerber W.D., Jäck A., Bille A., and Niederberger U. Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. Ann. Neurol. 25 (1989) 125-130
85. Diener H.C., Foeh M., Iaccarino C., Wessley P., Isler H.R., Strenge H., Fisher M., Wedekind W., and Taneri Z. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 16 (1996) 441-447
86. Diener H.C., Krupp P., Schmitt T., Steitz G., Milde K., Freytag S., and on behalf of the Study Group. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. Cephalalgia 21 (2001) 66-70
87. Diener H.C., Matias-Guiu J., Hartung E., Pfaffenrath V., Ludin H.P., Nappi G., and De Beukelaar F. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 22 (2002) 209-221
88. Diener H.C., Rahlfs V.W., and Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur. Neurol. 51 (2004) 89-97
89. Diener H.C., Tfelt-Hansen P., Dahlöf C., Láinez M.J., Sandrini G., Wang S.J., Neto W., Vijapurkar U., Doyle A., Jacobs D., and MIGR-003 Study Group. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J. Neurol. 251 (2004) 943-950
90. Diener H.C., Pfaffenrath V., Schnitker J., Friede M., and Henneicke-von Zepelin H.H. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention-a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 25 (2005) 1031-1041
91. Dodick D.W., and Silberstein S.D. Migraine prevention. Pract. Neurol. 7 (2007) 383-393
92. Dodick D.W., Mauskop A., Elkind A.H., DeGryse R., Brin M.F., Silberstein S.D., and BOTOX CDH Study Group. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45 (2005) 315-324
93. Dohi Y., Ohashi M., Sugiyama M., Takase H., Sato K., and Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens. Res. 26 (2003) 691-697
94. Dolly J.O., and Aoki K.R. The structure and mode of action of different botulinum toxins. Eur. J. Neurol. 13 (2006) S1-S9
95. Draves A.H., and Walker S.E. Parthenolide content of Canadian commercial feverfew preparations: label claims are misleading in most cases. Can. Pharm. J. 136 (2003) 23-30
96. Durham P.L. Calcitonin gene-related peptide (CGRP) and migraine. Headache 46 (2006) S3-S8
97. Durham P.L., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 (2004) 35-42
98. Eisenberg M.J., Brox A., and Bestawros A.N. Calcium channel blockers: an update. Am. J. Med. 116 (2004) 35-43
99. Elkayam U. Calcium channel blockers in heart failure. Cardiology 89 (1998) S38-S46
100. Elkind A.H., O'Carroll P., Blumenfeld A., DeGryse R., Dimitrova R., and BoNTA-024-026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J. Pain 7 (2006) 688-696
101. Evans R.W., and Taylor F.R. "Natural" or alternative medications for migraine prevention. Headache 46 (2006) 1012-1018
102. Evers S., Vollmer-Haase J., Schwaag S., Rahmann A., Husstedt I.W., and Frese A. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24 (2004) 838-843
103. Facchinetti F., Sances G., Bakalakis C., Morgillo M.G., Lottici P., Cicoli C., and Genazzani A.R. Neuroendocrine effects of flunarizine treatment in postmenopausal women. Cephalalgia 5 (1985) S187-S188
104. Ferrari M.D., Odink J., Bos K.D., Malessy M.J., and Bruyn G.W. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 40 (1990) 1582-1586
105. Fiebich B.L., Grozdeva M., Hess S., Hull M., Danesch U., Bodensieck A., and Bauer R. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med. 71 (2005) 12-19
106. Fink K., Meder W., Dooley D.J., and Gothert M. Inhibition of neuronal Ca++ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br. J. Pharmacol. 130 (2000) 900-906
107. Foran P.G., Davletov B., and Meunier F.A. Getting muscles moving again after botulinum toxin: novel therapeutic challenges. Trends Mol. Med. 9 (2003) 291-299
108. Forssman B., Henriksson K.G., and Kihlstrand S. A comparison between BC 105 and methysergide in the prophylaxis of migraine. Acta Neurol. Scand. 48 (1972) 204-212
109. Freitag F.G., Collins S.D., Carlson H.A., Goldstein J., Saper J., Silberstein S., Mathew N., Winner P.K., Deaton R., Sommerville K., Depakote E.R., and Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58 (2002) 1652-1659
110. Freitag F.G., Diamond S., Diamond M., and Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 48 (2008) 201-209
111. Gazerani P., Staahl C., Drewes A.M., and Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122 (2006) 315-325
112. 2+ channel blockers lidoflazine and flunarizine. Neurosci. Lett. 6 (1993) 97-100
113. Ghelardini C., Galeotti N., and Bartolini A. Antinociception induced by amitriptyline and imipramine is mediated by alpha2A-adrenoceptors. Jpn. J. Pharmacol. 82 (2000) 130-137
114. Gillies D., Sills M., and Forsythe I. Pizotifen (Sandomigran) in childhood migraine. A double-blind controlled trial. Eur. Neurol. 25 (1986) 32-35
115. Glazer W.M. Olanzapine and the new generation of antipsychotic agents: patterns of use. J. Clin. Psychiatry 58 (1997) 18-21
116. Goadsby P.J. Migraine pathophysiology. Headache 45 (2005) S14-S24
117. Goadsby P.J. Emerging therapies for migraine. Nat. Clin. Pract. Neurol. 3 (2007) 610-619
118. Goadsby P.J., and Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33 (1993) 48-56
119. Goadsby P.J., and Classey J.D. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 875 (2000) 119-124
120. Gómez-Pinilla F., Ying Z., Roy R.R., Hodgson J., and Edgerton V.R. Afferent input modulates eurotrophins and synaptic plasticity in the spinal cord. Neurophysiology 92 (2004) 3423-3432
121. Gonçalves T., Carvalho A.P., and Oliveira C.R. Antioxidant effect of calcium antagonists on microsomal membranes isolated from different brain areas. Eur. J. Pharmacol. 204 (1991) 315-322
122. Gorji A., Scheller D., Straub H., Tegtmeier F., Köhling R., Höhling J.M., Tuxhorn I., Ebner A., Wolf P., Werner Panneck H., Oppel F., and Speckmann E.J. Spreading depression in human neocortical slices. Brain Res. 906 (2001) 74-83
123. Graham J.R. Methysergide for prevention of headache: experience in five hundred patients over three years. N. Engl. J. Med. 270 (1964) 67-72
124. Graham J.R., and Wolf H.G. Mechanism of migraine headache and action of ergotamine tartrate. Arch. Neurol. Psychiatry 39 (1938) 737-763
125. Groenewegen W.A., and Heptinstall S.A. Comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J. Pharm. Pharmacol. 42 (1990) 553-557
126. Groth W., Blume A., Gohlke P., Unger T., and Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J. Hypertens. 21 (2003) 2175-2182
127. Grossman W., and Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern. Med. Rev. 6 (2001) 303-310
128. Gryder D.S., and Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 23 (2003) 7069-7074
129. Guido W., Lo F.S., and Erzurumlu R.S. Synaptic plasticity in the trigeminal principal nucleus during the period of barrelette formation and consolidation. Brain Res. Dev. 132 (2001) 97-102
130. Gupta V.K. Magnesium therapy for migraine: do we need more trials or more reflection?. Headache 44 (2004) 445-446
131. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 27 (2007) 1293-3000
132. Hanbauer I., Kopin I.J., Guidotti A., and Costa E. Induction of tyrosine hydroxylase elicited by beta adrenergic receptor agonists in normal and decentralized sympathetic ganglia: role of cyclic 3′,5′-adenosine monophosphate. J. Pharmacol. Exp. Ther. 193 (1975) 95-104
133. Harbige L.S. Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n - 6 and n - 3. Lipids 38 (2003) 323-341
134. Hays P. Paroxetine prevents migraines. J. Clin. Psychiatry 58 (1997) 30-31
135. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd ed. (ICHD-II). Cephalalgia 24 (2004) S9-S160
136. Hegerl U., and Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotoninergic neurotransmission: a new hypothesis. Biol. Psychiatry 33 (1993) 173-187
137. Hering R., and Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12 (1992) 81-84
138. Hieble J.P. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm. Acta Helv. 74 (2000) 163-171
139. Hladovec J., and De Clerck F. Protection by flunarizine against endothelial cell injury in vivo. Angiology 32 (1981) 448-462
140. Horne M.K., Lee J., Chen F., Lanning K., Tomas D., and Lawrence A.J. Long-term administration of cocaine or serotonin reuptake inhibitors results in anatomical and neurochemical changes in noradrenergic, dopaminergic, and serotonin pathways. J. Neurochem. 106 (2008) 1731-1744
141. Iqbal A., and Vanhoutte P.M. Flunarizine inhibits endothelium-dependent hypoxic facilitation in canine coronary arteries through an action on vascular smooth muscle. Br. J. Pharmacol. 95 (1988) 789-794
142. Ito H., Takemori K., and Suzuki T. Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury. J. Hypertens. 19 (2001) 591-597
143. Jakubowski M., McAllister P.J., Bajwa Z.H., Ward T.N., Smith P., and Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 125 (2006) 286-295
144. Jain N.K., and Kulkarni S.K. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. Ethnopharmacology 68 (1999) 251-259
145. Jen J.C., Wan J., Palos T.P., Howard B.D., and Baloh R.W. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology 65 (2005) 529-534
146. Jensen R., Brink T., and Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 44 (1994) 647-651
147. Johnson E.S., Kadam N.P., Hylands D.M., and Hylands P.J. Efficacy of feverfew as prophylactic treatment of migraine. Br. Med. J. 291 (1985) 569-573
148. Johnson M.P., Fernandez F., Colson N.J., and Griffiths L.R. A pahrmacogenomic evaluation of migraine therapy. Expert Opin. Pharmacother. 8 (2007) 1821-1835
149. 2C receptor blockade?. Life Sci. 54 (1994) 641-644
150. Kaminski R.M., Banerjee M., and Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46 (2004) 1097-1104
151. Kaube H., and Goadsby P.J. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur. Neurol. 34 (1994) 30-35
152. Kim H.C., and Chung M.K. Voltage-dependent sodium and calcium currents in acutely isolated adult rat trigeminal root ganglion neurons. J. Neurophysiol. 81 (1999) 1123-1134
153. Kim P., Shimokawa H., and Vanhoutte P.M. Dietary omega-3 fatty acids and endothelium-dependent responses in porcine cerebral arteries. Stroke 23 (1992) 407-413
154. Klapper J., and on behalf of the Divalproex Sodium Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17 (1997) 103-108
155. Knapp H.R. Dietary fatty acids in human thrombosis and hemostasis. Am. J. Clin. Nutr. 65 (1997) S1687-S1698
156. Knight Y.E., and Goadsby P.J. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine?. Neuroscience 106 (2001) 793-800
157. Knight Y.E., Bartsch T., Kaube H., and Goadsby P.J. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional gentic link for migraine?. J. Neurosci. 22 (2002) 1-6
158. Koella W.P. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur. J. Clin. Pharmacol. 28 (1985) 55-63
159. Kubo K., Yoshitake I., Kumada Y., Shuto K., and Nakamizo N. Radical scavenging action of flunarizine in rat brain in vitro. Arch. Int. Pharmacodyn. Ther. 272 (1984) 283-295
160. Kuzniecky R., Hetherington H., Ho S., Pan J., Martin R., Gilliam F., Hugg J., and Faught E. Topiramate increases cerebral GABA in healthy humans. Neurology 51 (1998) 627-629
161. Lampl C., Buzath A., Klinger D., and Neumann K. Lamotrigine in the prophylactic treatment of migraine aura-a pilot study. Cephalalgia 19 (1999) 58-63
162. Lampl C., Katsarava Z., Diener H.C., and Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1730-1732
163. Landy S., McGinnis J., Curlin D., and Laizure S.C. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 39 (1999) 28-32
164. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 117 (1994) 199-210
165. 2+-induced changes in SNAREs and synaptotagmin I correlate with triggered exocytosis from chromaffin cells: insights gleaned into the signal transduction using trypsin and botulinum toxins. J. Cell. Sci. 115 (2002) 2791-2800
166. Lawrence G.W., and Dolly J.O. Multiple forms of SNARE complexes in exocytosis from chromaffin cells: effects of Ca(2+). MgATP and botulinum toxin type A. J. Cell. Sci. 115 (2002) 667-673
167. Lazarov N., and Pilgrim C. Localization of D1 and D2 dopamine receptors in the rat mesencephalic trigeminal nucleus by immunocytochemistry and in situ hybridization. Neurosci. Lett. 236 (1997) 83-86
168. Lea R.A., Dohy A., Jordan K., Quinlan S., Brimage P.J., and Griffiths L.R. Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics 3 (2000) 35-40
169. Lenaz G., Fato R., Formiggini G., and Genova M.L. The role of coenzyme Q in mitochondrial electron transport. Mitochondrion 7 (2007) S8-S33
170. Lévy E., and Margolese H.C. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int. Clin. Psychopharmacol. 18 (2003) 301-303
171. Limmroth V., and Michel M.C. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br. J. Clin. Pharmacol. 52 (2001) 237-243
172. Linde K., and Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev. 2 (2004) CD003225
173. Lino-de-Oliveira C., de Oliveira R.M., Pádua Carobrez A., de Lima T.C., del Bel E.A., and Guimarães F.S. Antidepressant treatment reduces Fos-like immunoreactivity induced by swim stress in different columns of the periaqueductal gray matter. Brain Res. Bull. 70 (2006) 414-421
174. Lipton R.B., Gobel H., Einhaupl K.M., Wilks K., and Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63 (2004) 2240-2244
175. Littarru G.P., and Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol. Biotechnol. 37 (2007) 31-37
176. Littrell K.H., Petty R.G., and Wolf N.M. Olanzapine: a 5-year perspective. Expert Rev. Neurother. 6 (2006) 811-821
177. Lodi R., Iotti S., Cortelli P., Pierangeli G., Cevoli S., Clementi V., Soriani S., Montagna P., and Barbiroli B. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res. Bull. 54 (2001) 437-441
178. ®) in migraine treatment: a double-blind study. Cephalalgia 2 (1982) 197-203
179. Maestri E., Manzoni G.C., Marchesi G., Camellini L., Rossi G., Veneri G., and Gnudi A. Effect of flunarizine on pituitary secretion by healthy men and in woman with migraine. Eur. J. Clin. Pharmacol. 32 (1987) 525-527
180. Magnusson K.R., Larson A.A., Madl J.E., Altschuler R.A., and Beitz A.J. Co-localization of fixative-modified glutamate and glutaminase in neurons of the spinal trigeminal nucleus of the rat: an immunohistochemical and immunoradiochemical analysis. J. Comp. Neurol. 247 (1986) 477-490
181. Malick A., and Burstein R. Peripheral and central sensitization during migraine. Funct. Neurol. 15 (2000) S28-S35
182. Maneuf Y.P., and McKnight A.T. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br. J. Pharmacol. 134 (2001) 237-240
183. Maneuf Y.P., Blake R., Andrews N.A., and McKnight A.T. Reduction by gabapentin of K+-evoked release of (3H)-glutamate from the caudal trigeminal nucleus of the streptozocin-treated rat. Br. J. Pharmacol. 141 (2004) 574-579
184. Marrannes R., Willems R., De Prins E., and Wauquier A. Evidence for a role of the N-methyl-D-aspartate (NMDA) receptor in cortical spreading depression in the rat. Brain Res. 457 (1988) 226-240
185. Marriage B., Clandinin M.T., and Glerum D.M. Nutritional cofactor treatment in mitochondrial disorders. J. Am. Diet. Assoc. 103 (2003) 1029-1038
186. Martella G., Costa C., Pisani A., Cupini L.M., Bernardi G., and Calabresi P. Antiepileptic drugs on calcium currents recorded from cortical and PAG neurons: therapeutic implications for migraine. Cephalalgia 28 (2008) 1315-1326
187. Martínez H.R., Londoño O., Cantú-Martínez L., del Carmen Tarín L., and Castillo C.D. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 43 (2003) 1080-1084
188. Mathew N.T. Valproate in the prophylaxis of migraine. Cephalalgia 12 (1992) 67
189. Mathew N.T., Saper J., Silberstein S., Rankin L., Markley H., and Solomon S. Migraine prophylaxis with divalproex. Arch. Neurol. 52 (1995) 281-286
190. Mathew N.T., Rapoport A., Saper J., Magnus L., Klapper J., Ramadan N., Stacey B., and Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache 41 (2001) 119-128
191. Mauskop A., and Altura B.M. Role of magnesium in the pathogenesis and treatment of migraines. Clin. Neurosci. 5 (1998) 24-27
192. 2+ ratio. Headache 33 (1993) 135-138
193. May A., and Matharu M. New insights into migraine: application of functional and structural imaging. Curr. Opin. Neurol. 20 (2007) 306-309
194. McCarren T., Hitzemann R., Smith R., Kloss R., Allen C., and Gluek C.J. Amelioration of severe migraine by fish-oil (ω3) fatty acids. Clin. Res. 33 (1985) 275A
195. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
196. Mittra S., Datta A., Singh S.K., and Singh A. 5-Hydroxytryptamine-inhibiting property of Feverfew: role of parthenolide content. Acta Pharmacol. Sin. 21 (2000) 1106-1114
197. Moja P.L., Cusi C., Sterzi R.R., and Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst. Rev. 20 (2005) CD002919
198. Montastruc P., Dang-Tran L., Carvajal A., Rastin M., and Montastruc J.L. Naloxone reverses the effects of enalapril and enalaprilic acid on the pressure responses to afferent vagal stimulation. Neuropeptides 6 (1985) 537-542
199. Montagna P., Cortelli P., and Barbiroli B. Magnetic resonance spectroscopy studies in migraine. Cephalalgia 14 (1994) 184-193
200. Morey S.S. Guidelines on migraine: part 5. Recommendations for specific prophylactic drugs. Am. Fam. Physician 62 (2000) 2535-2539
201. Moskowitz M.A. The neurobiology of vascular head pain. Ann. Neurol. 16 (1984) 157-168
202. Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43 (1993) S16-S20
203. Moskowitz M.A. Genes, proteases, cortical spreading depression and migraine: impact on pathophysiology and treatment. Funct. Neurol. 22 (2007) 133-136
204. Mulleners W.M., and Chronicle E.P. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 28 (2008) 585-597
205. Murakami T., Okada M., Kawata Y., Zhu G., Kamata A., and Kaneko S. Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br. J. Pharmacol. 134 (2001) 507-520
206. Murphy J.J., Heptinstall S., and Mitchell J.R. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 2 (1988) 189-192
207. Mylecharane E.J. 5-HT2 receptor antagonists and migraine therapy. J. Neurol. 23 (1991) S45-S52
208. Nagtegaal J.E., Smits M.G., Swart A.C., Kerkhof G.A., and van der Meer Y.G. Melatonin-responsive headache in delayed sleep phase syndrome: preliminary observations. Headache 38 (1998) 303-307
209. Nagtegaal J.E., Laurant M.W., Kerkhof G.A., Smits M.G., van der Meer Y.G., and Coenen A.M. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J. Psychosom. Res. 48 (2000) 45-50
210. Nishikawa T., and Scatton B. Inhibitory influence of GABA on central serotonergic transmission. Involvement of the habenulo-raphé pathways in the GABAergic inhibition of ascending cerebral serotonergic neurons. Brain Res. 331 (1985) 81-90
211. Nyrke T., Kangasniemi P., Lang A.H., and Petersen E. Steady-state visual evoked potentials during migraine prophylaxis by propranolol and femoxetine. Acta Neurol. Scand. 69 (1984) 9-14
212. Oka M., Itoh Y., Wada M., Yamamoto A., and Fujita T. A comparison of Ca++ channel blocking mode between gabapentin and verapamil: implication for protection against hypoxic injury in rat cerebrocortical slices. Br. J. Pharmacol. 139 (2003) 435-443
213. Ondo W.G., Vuong K.D., and Derman H.S. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 24 (2004) 60-65
214. Owada K. Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens. Res. 27 (2004) 441-446
215. Ozkul Y., and Bozlar S. Effects of fluoxetine on habituation of pattern reversal visually evoked potentials in migraine prophylaxis. Headache 42 (2002) 582-587
216. Ozyalcin S.N., Talu G.K., Kiziltan E., Yucel B., Ertas M., and Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45 (2005) 144-152
217. Pakalnis A., Kring D., and Meier L. Levetiracetam prophylaxis in pediatric migraine-an open-label study. Headache 47 (2007) 427-430
218. Palevitch D., Earon G., and Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a placebo-controlled double-blind study. Phytother. Res. 11 (1997) 508-511
219. Paterna S., Di Pasquale P., D'Angelo A., Seidita G., Tuttolomondo A., Cardinale A., Maniscalchi T., Follone G., Giubilato A., Tarantello M., and Licata G. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur. Neurol. 43 (2000) 133-136
220. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 42 (1992) 2147-2152
221. Peres M.F. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 25 (2005) 403-411
222. Peres M.F., Zukerman E., Senne Soares C.A., Alonso E.O., Santos B.F., and Faulhaber M.H. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24 (2004) 735-739
223. Peroutka S.J., and Snyder S.H. Regulation of serotonin 2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J. Pharmacol. Exp. Ther. 215 (1980) 582-587
224. Peroutka S.J., Wilhoit T., and Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 49 (1997) 201-206
225. Pfaffenrath V., Diener H.C., Fischer M., Friede M., and Henneicke-von Zepelin H.H. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis-a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 22 (2002) 523-532
226. Phillips M.I., and de Oliveira E.M. Brain renin-angiotensin in disease. J. Mol. Med. 86 (2008) 715-722
227. Piccini P., Nuti A., Paoletti A.M., Napolitano A., Melis G.B., and Bonuccelli U. Possible involvement of dopaminergic mechanisms in the antimigraine action of flunarizine. Cephalalgia 10 (1990) 3-8
228. Pietrobon D. Migraine: new molecular mechanisms. Neuroscientist 11 (2005) 373-386
229. Pietrobon D. Function and dysfunction of synaptic calcium channels: insights from mouse models. Curr. Opin. Neurobiol. 15 (2005) 257-265
230. Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics 4 (2007) 274-284
231. Pietrobon D., and Striessnig J. Neurobiology of migraine. Nat. Rev. Neurosci. 4 (2003) 386-398
232. Pittler M.H., and Ernst E. Feverfew for preventing migraine. Cochrane Database Syst. Rev. (2004) CD002286
233. Pradalier A., Bakouche P., Baudesson G., Delage A., Cornaille-Lafage G., Launay J.M., and Biason P. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia 21 (2001) 818-822
234. Pringsheim T., Diksic M., Dobson C., Nguyen K., and Hamel E. Selective decrease in serotonin synthesis rate in rat brainstem raphe nuclei following chronic administration of low doses of amitriptyline: an effect compatible with an anti-migraine effect. Cephalalgia 23 (2003) 367-375
235. Prousky J., and Seely D. The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature. Nutr. J. 4 (2005) 3
236. Ramadan N.M. The link between glutamate and migraine. CNS Spectr. 8 (2003) 446-449
237. Ramadan N.M. Current trends in migraine prophylaxis. Headache 47 (2007) S52-S57
238. Rampello L., Alvano A., Chiechio S., Malaguarnera M., Raffaele R., Vecchio I., and Nicoletti F. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology 50 (2004) 322-328
239. Rascol A., Montastruc J.L., and Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 26 (1986) 83-85
240. Reuter U., Chiarugi A., Bolay H., and Moskowitz M.A. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann. Neurol. 51 (2002) 507-516
241. Reveiz-Herault L., Cardona A.F., Ospina E.G., and Carrillo P. Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature. Rev. Neurol. 36 (2003) 907-912
242. Riccioni G., Bucciarelli T., Mancini B., Di Ilio C., and D'Orazio N. Antileukotriene drugs: clinical application, effectiveness and safety. Curr. Med. Chem. 14 (2007) 1966-1977
243. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 65 (2005) S1-S10
244. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin. Proc. 65 (1990) 1227-1236
245. Richter F., Ebersberger A., and Schaible H.G. Blockade of voltage-gated calcium channels in rat inhibits repetetive cortical spreading depression. Neurosci. Lett. 334 (2002) 123-126
246. Richter F., Mikulik O., Ebersberger A., and Schaible H.G. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J. Cereb. Blood Flow Metab. 25 (2005) 1225-1235
247. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10 (2004) 685-692
248. Romero M., Sánchez I., and Pujol M.D. New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships. Curr. Med. Chem. Cardiovasc. Hematol. Agents 1 (2003) 113-141
249. Rozen T.D., Oshinsky M.L., Gebeline C.A., Bradley K.C., Young W.B., Shechter A.L., and Silberstein S.D. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22 (2002) 137-141
250. Russell M.B. Is migraine a genetic illness? The various forms of migraine share a common genetic cause. Neurol. Sci. 29 (2008) S52-S54
251. Samton J., and Mauskop A. Treatment of headaches with botulinum toxin. Expert Rev. Neurother. 6 (2006) 313-322
252. Sanchez-del-Rio M., and Reuter U. Migraine aura: new information on underlying mechanisms. Curr. Opin. Neurol. 17 (2004) 289-293
253. Sanchez-del-Rio M., Reuter U., and Moskowitz M.A. New insights into migraine pathophysiology. Curr. Opin. Neurol. 19 (2006) 294-298
254. Sándor P.S., and Afra J. Nonpharmacologic treatment of migraine. Curr. Pain Headache Rep. 9 (2005) 202-205
255. Sándor P.S., Afra J., Ambrosini A., and Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 40 (2000) 30-35
256. Sándor P.S., Ambrosini A., Agosti R.M., and Schoenen J. Genetics of migraine: possible links to neurophysiological abnormalities. Headache 42 (2002) 365-377
257. Sándor P.S., Dydak U., Schoenen J., Kollias S.S., Hess K., Boesiger P., and Agosti R.M. MR-spectroscopic imaging during visual stimulation in subgroups of migraine with aura. Cephalalgia 25 (2005) 507-518
258. Sándor P.S., Di Clemente L., Coppola G., Saenger U., Fumal A., Magis D., Seidel L., Agosti R.M., and Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64 (2005) 713-715
259. Sarchielli P., Coata G., Firenze C., Morucci P., Abbritti G., and Gallai V. Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult patients. Cephalalgia 12 (1992) 21-27
260. Sarchielli P., Alberti A., Codini M., Floridi A., and Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20 (2000) 907-918
261. Sarchielli P., Tarducci R., Presciutti O., Gobbi G., Pelliccioli G.P., Stipa G., Alberti A., and Capocchi G. Functional 1H-MRS findings in migraine patients with and without aura assessed interictally. Neuroimage 24 (2005) 1025-1031
262. Sarchielli P., Di Filippo M., Nardi K., and Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr. Pain Headache Rep. 11 (2007) 343-351
263. Sarchielli P., Pini L.A., Coppola F., Rossi C., Baldi A., Mancini M.L., and Calabresi P. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 32 (2007) 1384-1390
264. Schellenberg R., Lichtenthal A., Wöhling H., Graf C., and Brixius K. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?. Headache 48 (2008) 118-125
265. Scher A.I., Stewart W.F., Liberman J., and Lipton R.B. Prevalence of frequent headache in a population sample. Headache 38 (1998) 497-506
266. Schoenen J. Neurophysiological features of the migrainous brain. Neurol. Sci. 27 (2006) S77-S81
267. Schoenen J., Maertens de Noordhout A., Timsit-Berthier M., and Timsit M. Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia 6 (1986) 229-233
268. Schoenen J., Jacquy J., and Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50 (1998) 466-470
269. Schoenen J., Ambrosini A., Sándor P.S., and Maertens de Noordhout A. Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance. Clin. Neurophysiol. 114 (2003) 955-972
270. Schrader H., Stovner L.J., Helde G., Sand T., and Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 322 (2001) 19-22
271. Schreiber S., Getslev V., Backer M.M., Weizman R., and Pick C.G. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol. Biochem. Behav. 64 (1999) 75-80
272. Schuh-Hofer S., Flach U., Meisel A., Israel H., Reuter U., and Arnold G. Efficacy of lisinopril in migraine prophylaxis-an open label study. Eur. J. Neurol. 14 (2007) 701-703
273. Schwedt T.J., and Dodick D.W. Advanced neuroimaging of migraine. Lancet Neurol. 8 (2009) 560-568
274. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 (2002) 27-38
275. Shank R.P., Gardocki J.F., Streeter A.J., and Maryanoff B.E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacoknetics and mechanism of action. Epilepsia 41 (2000) S3-S9
276. Sheftell F., Rapoport A., Weeks R., Walker B., Gammerman I., and Baskin S. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 40 (2000) 158-163
277. Shibata K. Neurophysiology of visual aura in migraine. Brain Nerve 59 (2007) 961-970
278. Shrivastava R., Pechadre J.C., and John G.W. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin. Drug Investig. 26 (2006) 287-296
279. Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia 1 (1981) 229-232
280. Silberstein S.D. Methysergide. Cephalalgia 18 (1998) 421-435
281. Silberstein S.D. Preventive treatment of migraine. Trends Pharmacol. Sci. 27 (2006) 410-415
282. Silberstein S.D., and Goadsby P.J. Migraine: preventive treatment. Cephalalgia 22 (2002) 491-512
283. Silberstein S.D., and Goldberg J. Menstrually related migraine: breaking the cycle in your clinical practice. J. Reprod. Med. 52 (2007) 888-895
284. Silberstein S.D., Goadsby P.J., and Lipton R.B. Management of migraine: an algorithmic approach. Neurology 55 (2000) S46-S52
285. Silberstein S.D., Peres M.F., Hopkins M.M., Shechter A.L., Young W.B., and Rozen T.D. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 42 (2002) 515-518
286. Silberstein S.D., Neto W., Schmitt J., Jacobs D., and MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61 (2004) 490-495
287. Silberstein S.D., Dodick D., Freitag F., Pearlman S.H., Hahn S.R., Scher A.I., and Lipton R.B. Pharmacological approaches to managing migraine and associated comorbidities-clinical considerations for monotherapy versus polytherapy. Headache 47 (2007) 585-599
288. Silberstein S.D., Tfelt-Hansen P., Dodick D.W., Limmroth V., Lipton R.B., Pascual J., and Wang S.J. Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28 (2008) 484-495
289. Silva E., Hernandez L., Contreras Q., Guerrero F., and Alba G. Noxious stimulation increases glutamate and arginine in the periaqueductal gray matter in rats: a microdialysis study. Pain 87 (2000) 131-135
290. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 33 (1981) 155-188
291. Siniatchkin M., Andrasik F., Kropp P., Niederberger U., Strenge H., Averkina N., Lindner V., Stephani U., and Gerber W.D. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia 27 (2007) 1024-1032
292. Smuts J.A., Schultz D., and Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 44 (2004) 801-805
293. Sommer C. Is serotonin hyperalgesic or analgesic?. Curr. Pain Headache Rep. 10 (2006) 101-106
294. Sorensen K.V. Valproate: a new drug in migraine prophylaxis. Acta Neurol. Scand. 78 (1988) 346-348
295. Sparaco M., Feleppa M., Lipton R.B., Rapoport A.M., and Bigal M.E. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 26 (2006) 361-372
296. Speight T.M., and Avery G.S. Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headache. Drugs 3 (1972) 159-203
297. Srikiatkhachorn A., Puangniyom S., and Govitrapong P. Plasticity of 5-HT serotonin receptor in patients with analgesic-induced transformed migraine. Headache 38 (1998) 534-549
298. Stahl S.M., Grady M.M., Moret C., and Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10 (2005) 732-747
299. Steiner T.J., Findley L.J., and Yuen A.W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17 (1997) 109-112
300. Stewart W.F., Lipton R.B., and Liberman J. Variation in migraine prevalence by race. Neurology 47 (1996) 52-59
301. Storey J.R., Calder C.S., Hart D.E., and Potter D.L. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41 (2001) 968-975
302. Stovner L.J. Migraine prophylaxis with drugs influencing the renin-angiotensin system. Eur. J. Neurol. 14 (2007) 713-714
303. Takei M., Hiramatsu M., and Mori A. Inhibitory effects of calcium antagonists on mitochondrial swelling induced by lipid peroxidation or arachidonic acid in the rat brain in vitro. Neurochem. Res. 19 (1994) 1199-1206
304. Tallksen-Greene S.J., Young A.B., Penney J.B., and Beitz A.J. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci. Lett. 141 (1992) 79-83
305. Tanaka J., Nagai T., Arai H., Inui K., Yamanouchi H., Goto Y., Nonaka I., and Okada S. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. Brain Dev. 19 (1997) 262-267
306. Tassorelli C., Greco R., Morazzoni P., Riva A., Sandrini G., and Nappi G. Parthenolide is the component of Tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 25 (2005) 612-621
307. Taverna S., Mantegazza M., Franceschetti S., and Avanzini G. Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons. Epilepsy Res. 32 (1998) 304-308
308. Taverna S., Sancini G., Mantegazza M., Franceschetti S., and Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 288 (1999) 960-968
309. Taylor A.P., Adelman J.U., and Freeman M.C. Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review. Headache 47 (2007) 1200-1203
310. Tepper S.J., Bigal M.E., Sheftell F.D., and Rapoport A.M. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache 44 (2004) 794-800
311. Tfelt-Hansen P. Efficacy of beta-blockers in migraine. A critical review. Cephalalgia 6 (1986) S15-S24
312. Thomet O.A., Wiesmann U.N., Schapowal A., Bizer C., and Simon H.U. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem. Pharmacol. 61 (2001) 1041-1104
313. Togha M., Ashrafian H., and Tajik P. Open-label trial of cinnarizine in migraine prophylaxis. Headache 46 (2006) 498-503
314. Togha M., Rahmat Jirde M., Nilavari K., Ashrafian H., Razeghi S., and Kohan L. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. J. Headache Pain 9 (2008) 77-82
315. Tozzi-Ciancarelli M.G., De Matteis G., Di Massimo C., Marini C., Ciancarelli I., and Carolei A. Oxidative stress and platelet responsiveness in migraine. Cephalalgia 17 (1997) 580-584
316. Triggle D.J. L-type calcium channels. Curr. Pharm. Des. 12 (2006) 443-457
317. Tronvik E., Stovner L.J., Helde G., Sand T., and Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289 (2003) 65-69
318. Tronvik E., Stovner L.J., Schrader H., and Bovim G. Involvement of the renin-angiotensin system in migraine. J. Hypertens. Suppl. 24 (2006) S139-S143
319. Van den Maagdenberg A.M., Pietrobon D., Pizzorusso T., Kaja S., Broos L.A., Cesetti T., van de Ven R.C., Trottene A., van der Kaa J., Plomp J.J., Frants R.R., and Ferrari M.D. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 41 (2004) 679-680
320. Velling D.A., Dodick D.W., and Muir J.J. Sustained-release niacin for prevention of migraine headache. Mayo Clin. Proc. 78 (2003) 770-771
321. Vikelis M., and Mitsikostas D.D. The role of glutamate and its receptors in migraine. CNS Neurol. Disord. Drug Targets 6 (2007) 251-257
322. Vilming S., Standnes B., and Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine: a double-blind investigation. Cephalalgia 5 (1985) 17-23
323. Vogler B.K., Pittler B.K., and Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 18 (1998) 704-708
324. Vogler B.K., Rapoport A.M., Tepper S.J., Sheftell F., and Bigal M.E. Role of melatonin in the pathophysiology of migraine: implications for treatment. CNS Drugs 20 (2006) 343-350
325. Wang F., Van Den Eeden S.K., Ackerson L.M., Salk S.E., Reince R.H., and Elin R.J. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43 (2003) 601-610
326. 2+ channel blocking effect of iso-S-petasin in rat aortic smooth muscle cells. Eur. J. Pharmacol. 445 (2002) 239-245
327. Wauquier A., Ashton D., and Marrannes R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 5 (1985) S119-S123
328. Weber M.A. Calcium channel antagonists in the treatment of hypertension. Am. J. Cardiovasc. Drugs 2 (2002) 415-431
329. Weiller C., May A., Limmroth V., Jüptner M., Kaube H., Schayck R.V., Coenen H.H., and Diener H.C. Brainstem activation in spontaneous human migraine attacks. Nat. Med. 1 (1995) 658-660
330. Welch K.M. Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention. Headache 45 (2005) S25-S32
331. Welch K.M., and Ramadan N.M. Mitochondria, magnesium and migraine. J. Neurol. Sci. 134 (1995) 9-14
332. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
333. Welch K.M., Nagesh V., Sheena K.A., and Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness. Headache 41 (2001) 629-637
334. Wessman M., Terwindt G.M., Kaunisto M.A., Palotie A., and Ophoff R.A. Migraine: a complex genetic disorder. Lancet Neurol. 6 (2007) 521-532
335. White H.S., Borown S.D., Woodhead J.H., Skeen G.A., and Wolf H.H. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41 (2000) S17-S20
336. Wiedemann M., de Lima V.M., and Hanke W. Effects of antimigraine drugs on retinal spreading depression. Naunyn Schmiedebergs Arch. Pharmacol. 353 (1996) 552-556
337. Wöber C., Brücke T., Wöber-Bingöl C., Asenbaum S., Wessely P., and Podreka I. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia 14 (1994) 235-240
338. Wu S.N., Chen H., and Lin Y.L. The mechanism of inhibitory actions of S-petasin, a sesquiterpene of Petasites formosanus, on L-type calcium current in NG108-15 neuronal cells. Planta Med. 69 (2002) 118-124
339. Xiao C., Zhou C., Atlas G., Delphin E., and Ye J.H. Labetalol facilitates GABAergic transmission to rat periaqueductal gray neurons via antagonizing beta1 adrenergic receptors-a possible mechanism underlying labetalol-induced analgesia. Brain Res. 1198 (2008) 34-43
340. Young W.B., and Rozen T.D. Preventive treatment of migraine: effect on weight. Cephalalgia 25 (2005) 1-11
341. Yu W., and Horowitz S.H. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 60 (2003) 120-121
342. Zhang X.C., Strassman A.M., Burstein R., and Levy D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J. Pharmacol. Exp. Ther. 322 (2007) 806-812